Cargando…

Vogt-Koyanagi-Harada disease following influenza vaccination

PURPOSE: To report a case of Vogt–Koyanagi–Harada (VKH) disease following influenza vaccination. OBSERVATIONS: A 30-year-old Filipino male developed bilateral pain, redness, photophobia, floaters, headache and tinnitus 2 days after receiving the annual influenza vaccine. He presented to the emergenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Murtaza, Fahmeeda, Pereira, Austin, Mandelcorn, Mark S., Kaplan, Alexander J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020092/
https://www.ncbi.nlm.nih.gov/pubmed/35464684
http://dx.doi.org/10.1016/j.ajoc.2022.101516
_version_ 1784689456275521536
author Murtaza, Fahmeeda
Pereira, Austin
Mandelcorn, Mark S.
Kaplan, Alexander J.
author_facet Murtaza, Fahmeeda
Pereira, Austin
Mandelcorn, Mark S.
Kaplan, Alexander J.
author_sort Murtaza, Fahmeeda
collection PubMed
description PURPOSE: To report a case of Vogt–Koyanagi–Harada (VKH) disease following influenza vaccination. OBSERVATIONS: A 30-year-old Filipino male developed bilateral pain, redness, photophobia, floaters, headache and tinnitus 2 days after receiving the annual influenza vaccine. He presented to the emergency department 5 days after symptom onset. His past medical and ocular history was unremarkable. His best-corrected distance visual acuity (BCVA) was 20/100 in the right eye (OD) and 20/150 in the left eye (OS). Slit-lamp examination revealed fine keratic precipitates and 1+ anterior chamber cells in both eyes (OU). Dilated fundus examination revealed 1+ vitreous cells with trace haze and multiple serous retinal detachments OU. Magnetic resonance imaging (MRI) of the brain and chest X-ray were unremarkable. Serologic testing was negative for infectious, inflammatory and neoplastic causes. The patient tested positive for HLA-DR4. A diagnosis of acute Vogt-Koyanagi-Harada disease was made and high-dose oral prednisone, intravitreal triamcinolone acetonide and mycophenolate mofetil were needed to achieve quiescence. At 6 months follow-up, our patient remains in remission with no active intraocular inflammation or subretinal fluid. His BCVA has improved to 20/50 OD and 20/30 OS. CONCLUSION AND IMPORTANCE: The annual influenza vaccine may be a trigger for onset or recurrence of VKH in genetically susceptible individuals.
format Online
Article
Text
id pubmed-9020092
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90200922022-04-21 Vogt-Koyanagi-Harada disease following influenza vaccination Murtaza, Fahmeeda Pereira, Austin Mandelcorn, Mark S. Kaplan, Alexander J. Am J Ophthalmol Case Rep Case Report PURPOSE: To report a case of Vogt–Koyanagi–Harada (VKH) disease following influenza vaccination. OBSERVATIONS: A 30-year-old Filipino male developed bilateral pain, redness, photophobia, floaters, headache and tinnitus 2 days after receiving the annual influenza vaccine. He presented to the emergency department 5 days after symptom onset. His past medical and ocular history was unremarkable. His best-corrected distance visual acuity (BCVA) was 20/100 in the right eye (OD) and 20/150 in the left eye (OS). Slit-lamp examination revealed fine keratic precipitates and 1+ anterior chamber cells in both eyes (OU). Dilated fundus examination revealed 1+ vitreous cells with trace haze and multiple serous retinal detachments OU. Magnetic resonance imaging (MRI) of the brain and chest X-ray were unremarkable. Serologic testing was negative for infectious, inflammatory and neoplastic causes. The patient tested positive for HLA-DR4. A diagnosis of acute Vogt-Koyanagi-Harada disease was made and high-dose oral prednisone, intravitreal triamcinolone acetonide and mycophenolate mofetil were needed to achieve quiescence. At 6 months follow-up, our patient remains in remission with no active intraocular inflammation or subretinal fluid. His BCVA has improved to 20/50 OD and 20/30 OS. CONCLUSION AND IMPORTANCE: The annual influenza vaccine may be a trigger for onset or recurrence of VKH in genetically susceptible individuals. Elsevier 2022-04-10 /pmc/articles/PMC9020092/ /pubmed/35464684 http://dx.doi.org/10.1016/j.ajoc.2022.101516 Text en © 2022 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Murtaza, Fahmeeda
Pereira, Austin
Mandelcorn, Mark S.
Kaplan, Alexander J.
Vogt-Koyanagi-Harada disease following influenza vaccination
title Vogt-Koyanagi-Harada disease following influenza vaccination
title_full Vogt-Koyanagi-Harada disease following influenza vaccination
title_fullStr Vogt-Koyanagi-Harada disease following influenza vaccination
title_full_unstemmed Vogt-Koyanagi-Harada disease following influenza vaccination
title_short Vogt-Koyanagi-Harada disease following influenza vaccination
title_sort vogt-koyanagi-harada disease following influenza vaccination
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020092/
https://www.ncbi.nlm.nih.gov/pubmed/35464684
http://dx.doi.org/10.1016/j.ajoc.2022.101516
work_keys_str_mv AT murtazafahmeeda vogtkoyanagiharadadiseasefollowinginfluenzavaccination
AT pereiraaustin vogtkoyanagiharadadiseasefollowinginfluenzavaccination
AT mandelcornmarks vogtkoyanagiharadadiseasefollowinginfluenzavaccination
AT kaplanalexanderj vogtkoyanagiharadadiseasefollowinginfluenzavaccination